Preclinical evaluation of the CD38‐targeting engineered toxin body MT‐0169 against multiple myeloma

Preclinical evaluation of the CD38‐targeting engineered toxin body MT‐0169 against multiple myeloma

Abstract Despite significant progress in the treatment of multiple myeloma (MM), relapsed/refractory patients urgently require more effective therapies. We here describe the discovery, mechanism of action, and preclinical anti‐MM activity of engineered toxin body MT‐0169, a next‐generation immunotox...

Full description

Saved in:
Bibliographic Details
Main Authors: Wassilis S. C. Bruins, Rosa Rentenaar, John Newcomb, Wenrou Zheng, Ruud W. J. Ruiter, Thomas Baardemans, Eric Poma, Chris Moore, Garrett L. Robinson, Anya Lublinsky, Yuhong Zhang, Sakeena Syed, Michael Milhollen, Ajeeta B. Dash, Niels W. C. J. van deDonk, Richard W. J. Groen, Sonja Zweegman, Tuna Mutis
Format: Article
Language:English
Published: Wiley 2024-11-01
Series:HemaSphere
Online Access:https://doi.org/10.1002/hem3.70039
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1002/hem3.70039

Similar Items